AN2 Therapeutics Files Routine 8-K for 'Other Events'
Ticker: ANTX · Form: 8-K · Filed: Feb 12, 2024 · CIK: 1880438
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, administrative
TL;DR
**AN2 Therapeutics filed a routine 8-K with no new material news.**
AI Summary
AN2 Therapeutics, Inc. filed an 8-K on February 12, 2024, to report an "Other Event." This filing primarily serves to update the public record regarding the company's status and basic corporate information, such as its address at 1800 El Camino Real, Suite D, Menlo Park, California, and its trading symbol ANTX on The Nasdaq Stock Market LLC. For investors, this filing indicates routine compliance and does not contain new material financial or operational news, meaning there's no immediate impact on the stock price from this specific report.
Why It Matters
This filing is a standard regulatory update, providing no new material information that would typically affect AN2 Therapeutics' stock price or investment thesis. It's important for maintaining transparency but doesn't signal any operational changes.
Risk Assessment
Risk Level: low — This 8-K filing is purely administrative and does not introduce any new financial, operational, or legal risks to the company.
Analyst Insight
A smart investor would recognize this as a standard, non-event filing and would not make any investment decisions based solely on this particular 8-K. It's important to monitor for more substantive filings like 10-Qs or 10-Ks for material information.
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — the registrant filing the 8-K
- February 12, 2024 (date) — date of earliest event reported and filing date
- 001-41331 (other) — Commission File Number
- ANTX (other) — trading symbol for Common Stock
- The Nasdaq Stock Market LLC (other) — exchange where ANTX is registered
- 1800 El Camino Real, Suite D, Menlo Park, California, 94027 (other) — principal executive offices address
FAQ
What is the purpose of this specific 8-K filing by AN2 Therapeutics, Inc.?
This 8-K filing is categorized under 'Other Events' and primarily serves as a routine regulatory update, confirming the company's basic information and compliance with SEC reporting requirements as of February 12, 2024.
What is AN2 Therapeutics, Inc.'s trading symbol and on which exchange is it listed?
AN2 Therapeutics, Inc.'s trading symbol is ANTX, and its Common Stock is registered on The Nasdaq Stock Market LLC (Nasdaq Global Select Market).
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is February 12, 2024.
Where are AN2 Therapeutics, Inc.'s principal executive offices located?
AN2 Therapeutics, Inc.'s principal executive offices are located at 1800 El Camino Real, Suite D, Menlo Park, California, 94027.
Does this 8-K filing contain any information about new financial results or operational changes?
No, this 8-K filing, categorized as 'Other Events,' does not contain any information about new financial results, operational changes, or other material news that would typically impact the company's business or stock performance.
Filing Stats: 1,243 words · 5 min read · ~4 pages · Grade level 16.3 · Accepted 2024-02-12 07:01:31
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share ANTX The Nasdaq
Filing Documents
- d744326d8k.htm (8-K) — 29KB
- 0001193125-24-031008.txt ( ) — 154KB
- antx-20240212.xsd (EX-101.SCH) — 3KB
- antx-20240212_lab.xml (EX-101.LAB) — 18KB
- antx-20240212_pre.xml (EX-101.PRE) — 11KB
- d744326d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered "forward-looking statements," including, without limitation, statements regarding: further evaluation of the Company's study data and DSMB review; potential changes to the Company's Phase 3 study protocol; anticipated impact of clinical studies and timing for announcing results; timing of completion of the Company's analysis of study data; and continuation of enrolled patients in the Company's Phase 2/3 trial. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the Company's studies, trials, and development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation: the recommendations of the DSMB following its review of blinded data; the number of patients who remain enrolled in the Company's Phase 2/3 trial; the ability of the Company to resume enrollment in its Phase 2/3 trial, in the event the determination to resume enrollment is made; the Company's ability to effectively and timely make amendments to the Phase 2/3 pivotal trial design based on its analysis of the Phase 2 portion of the study and/or pursuant to additional feedback from the U.S. Food and Drug Administration; possible changes to the Company's plans or priorities as it assesses study data; potential for protocol modifications, redesign or study termination; timely enrollment of patients in the Company's existing and future clinical
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AN2 Therapeutics, Inc. Date: February 12, 2024 By: /s/ Eric Easom Eric Easom Chief Executive Officer